The development of therapies for neuropsychiatric disorders is hampered by the lack of understanding of the mechanisms underlying their pathologies. While aberrant sphingolipid metabolism is associated with psychiatric illness, the role of sphingolipids in these disorders is not understood. The genetically tractable yeast model can be exploited in order to elucidate the cellular consequences of sphingolipid perturbation. Hypotheses generated from studies in yeast and tested in mammalian cells may contribute to our understanding of the role of sphingolipids in psychiatric disorders and to the development of new treatments. Here, we compare sphingolipid metabolism in yeast and mammalian cells, discuss studies implicating sphingolipids in psychiatric disorders and propose approaches that utilize yeast in order to elucidate sphingolipid function and identify drugs that target sphingolipid synthesis.
The development of therapies for neuropsychiatric disorders is hampered by the lack of understanding of the mechanisms underlying their pathologies. While aberrant n class="Chemical">sphingolipid metabolism is associated with psychiatric illness, the role of sphingolipids in these disorders is not understood. The genetically tractable yeast model can be exploited in order to elucidate the cellular consequences of sphingolipid perturbation. Hypotheses generated from studies in yeast and tested in mammalian cells may contribute to our understanding of the role of sphingolipids in psychiatric disorders and to the development of new treatments. Here, we compare sphingolipid metabolism in yeast and mammalian cells, discuss studies implicating sphingolipids in psychiatric disorders and propose approaches that utilize yeast in order to elucidate sphingolipid function and identify drugs that target sphingolipid synthesis.
Authors: M Verheij; R Bose; X H Lin; B Yao; W D Jarvis; S Grant; M J Birrer; E Szabo; L I Zon; J M Kyriakis; A Haimovitz-Friedman; Z Fuks; R N Kolesnick Journal: Nature Date: 1996-03-07 Impact factor: 49.962
Authors: Kenneth L Davis; Daniel G Stewart; Joseph I Friedman; Monte Buchsbaum; Philip D Harvey; Patrick R Hof; Joseph Buxbaum; Vahram Haroutunian Journal: Arch Gen Psychiatry Date: 2003-05
Authors: Ayşe Demirkan; Aaron Isaacs; Peter Ugocsai; Gerhard Liebisch; Maksim Struchalin; Igor Rudan; James F Wilson; Peter P Pramstaller; Ulf Gyllensten; Harry Campbell; Gerd Schmitz; Ben A Oostra; Cornelia M van Duijn Journal: J Psychiatr Res Date: 2012-11-30 Impact factor: 4.791
Authors: Cathryn M Lewis; Douglas F Levinson; Lesley H Wise; Lynn E DeLisi; Richard E Straub; Iiris Hovatta; Nigel M Williams; Sibylle G Schwab; Ann E Pulver; Stephen V Faraone; Linda M Brzustowicz; Charles A Kaufmann; David L Garver; Hugh M D Gurling; Eva Lindholm; Hilary Coon; Hans W Moises; William Byerley; Sarah H Shaw; Andrea Mesen; Robin Sherrington; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael C O'Donovan; Michael J Owen; Dieter B Wildenauer; Wolfgang Maier; Gerald Nestadt; Jean-Louis Blouin; Stylianos E Antonarakis; Bryan J Mowry; Jeremy M Silverman; Raymond R Crowe; C Robert Cloninger; Ming T Tsuang; Dolores Malaspina; Jill M Harkavy-Friedman; Dragan M Svrakic; Anne S Bassett; Jennifer Holcomb; Gursharan Kalsi; Andrew McQuillin; Jon Brynjolfson; Thordur Sigmundsson; Hannes Petursson; Elena Jazin; Tomas Zoëga; Tomas Helgason Journal: Am J Hum Genet Date: 2003-06-11 Impact factor: 11.025